Herpesvirus Infections Potentiated by Biologics.
Alphaherpesvirinae
/ drug effects
Biological Products
/ adverse effects
Herpesviridae Infections
/ chemically induced
Herpesvirus 1, Human
/ physiology
Herpesvirus 2, Human
/ physiology
Herpesvirus 3, Human
/ physiology
Humans
Immunosuppressive Agents
/ adverse effects
Virus Activation
Virus Latency
/ drug effects
Biologic agents
Cytomegalovirus
Herpes simplex
Herpesvirus
Varicella-zoster
Journal
Infectious disease clinics of North America
ISSN: 1557-9824
Titre abrégé: Infect Dis Clin North Am
Pays: United States
ID NLM: 8804508
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
entrez:
24
5
2020
pubmed:
24
5
2020
medline:
16
3
2021
Statut:
ppublish
Résumé
Herpesviruses such as herpes simplex virus (HSV) type 1 and 2, varicella-zoster virus (VZV), and cytomegalovirus (CMV) maintain lifelong latency in the host after primary infection and can reactivate periodically either as asymptomatic viral shedding or as clinical disease. Immunosuppression, including biologic therapy, may increase frequency and severity of herpesvirus reactivation and infection. Licensed biologics are reviewed regarding their risks of potentiating HSV, VZV, and CMV reactivation and infection. Approaches to prophylaxis against HSV, VZV, and CMV infection or reactivation are discussed.
Identifiants
pubmed: 32444012
pii: S0891-5520(20)30008-8
doi: 10.1016/j.idc.2020.02.006
pii:
doi:
Substances chimiques
Biological Products
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
311-339Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.